Source comparison
Best Tesamorelin Dosage NASH Support 2026: Treatment Comparison
Tesamorelin 2mg daily GHRH analogue → GH secretion → VAT lipolysis 31–37% in VAT+ patients VAT >1600 cm³ required Off-label (approved for HIV lipodystrophy) Most effective in visceral-adiposity-driven NASH; requires sustained use; no benefit in lean NASH pheno
This comparison does not assign a generated winner or score.
- Tesamorelin 2mg daily
- GHRH analogue → GH secretion → VAT lipolysis
- 31–37% in VAT+ patients
- VAT >1600 cm³ required
- Off-label (approved for HIV lipodystrophy)
- Most effective in visceral-adiposity-driven NASH; requires sustained use; no benefit in lean NASH phenotypes
- Semaglutide 2.4mg weekly
- GLP-1 receptor agonist → appetite suppression + insulin sensitivity
- 25–35% (weight-loss-mediated)
- No VAT threshold
- Off-label (approved for obesity)
- Broader applicability; hepatic benefit proportional to total weight loss; GI side effects limit tolerability in 20–30%
- Pioglitazone 30–45mg daily
- PPAR-gamma agonist → insulin sensitisation + adipocyte differentiation
- 15–25%
- Off-label (approved for T2DM)
- Established histological efficacy; weight gain (+3–5kg) and fluid retention limit use in heart failure or osteoporosis risk
- Vitamin E 800 IU daily
- Antioxidant (mechanism unclear in NASH)
- 10–18% (non-diabetic only)
- Not FDA-regulated as drug
- Minimal hepatic benefit in diabetic NASH; increased prostate cancer risk in men limits long-term use
- Resmetirom 80–100mg daily
- THR-beta agonist → hepatic lipid oxidation
- 30–40%
- Under FDA review (Phase 3 completed)
- Direct hepatic mechanism; thyroid-like side effects (diarrhoea, nausea); promising histological data but long-term safety unknown